Logo image of PMN

PROMIS NEUROSCIENCES INC (PMN) Stock Fundamental Analysis

USA - NASDAQ:PMN - CA74346M4065 - Common Stock

0.411 USD
0 (-0.99%)
Last: 11/3/2025, 7:14:58 PM
0.419 USD
+0.01 (+1.95%)
After Hours: 11/3/2025, 7:14:58 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to PMN. PMN was compared to 534 industry peers in the Biotechnology industry. Both the profitability and financial health of PMN have multiple concerns. PMN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PMN had negative earnings in the past year.
In the past year PMN has reported a negative cash flow from operations.
In the past 5 years PMN always reported negative net income.
PMN had a negative operating cash flow in each of the past 5 years.
PMN Yearly Net Income VS EBIT VS OCF VS FCFPMN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

PMN has a worse Return On Assets (-88.62%) than 72.66% of its industry peers.
Industry RankSector Rank
ROA -88.62%
ROE N/A
ROIC N/A
ROA(3y)-137.72%
ROA(5y)-229.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PMN Yearly ROA, ROE, ROICPMN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K

1.3 Margins

PMN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PMN Yearly Profit, Operating, Gross MarginsPMN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10K -20K -30K -40K

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, PMN has more shares outstanding
Compared to 5 years ago, PMN has more shares outstanding
PMN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PMN Yearly Shares OutstandingPMN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
PMN Yearly Total Debt VS Total AssetsPMN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

PMN has an Altman-Z score of -24.35. This is a bad value and indicates that PMN is not financially healthy and even has some risk of bankruptcy.
PMN has a Altman-Z score of -24.35. This is amonst the worse of the industry: PMN underperforms 86.89% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -24.35
ROIC/WACCN/A
WACCN/A
PMN Yearly LT Debt VS Equity VS FCFPMN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

PMN has a Current Ratio of 0.97. This is a bad value and indicates that PMN is not financially healthy enough and could expect problems in meeting its short term obligations.
PMN has a worse Current ratio (0.97) than 87.45% of its industry peers.
A Quick Ratio of 0.97 indicates that PMN may have some problems paying its short term obligations.
PMN has a Quick ratio of 0.97. This is amonst the worse of the industry: PMN underperforms 86.89% of its industry peers.
Industry RankSector Rank
Current Ratio 0.97
Quick Ratio 0.97
PMN Yearly Current Assets VS Current LiabilitesPMN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 88.75% over the past year.
EPS 1Y (TTM)88.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-123.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PMN will show a small growth in Earnings Per Share. The EPS will grow by 7.11% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y94.81%
EPS Next 2Y6.4%
EPS Next 3Y8.93%
EPS Next 5Y7.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PMN Yearly Revenue VS EstimatesPMN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2017 2018 2019 2028 2029 2030 50M 100M 150M 200M 250M
PMN Yearly EPS VS EstimatesPMN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PMN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PMN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PMN Price Earnings VS Forward Price EarningsPMN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PMN Per share dataPMN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.4%
EPS Next 3Y8.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PMN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROMIS NEUROSCIENCES INC

NASDAQ:PMN (11/3/2025, 7:14:58 PM)

After market: 0.419 +0.01 (+1.95%)

0.411

0 (-0.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-12 2025-11-12
Inst Owners25.44%
Inst Owner Change0.01%
Ins Owners4.51%
Ins Owner Change2.45%
Market Cap22.12M
Revenue(TTM)N/A
Net Income(TTM)-8427300
Analysts82.5
Price Target5.74 (1296.59%)
Short Float %0.5%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-68.67%
Min EPS beat(2)-73.27%
Max EPS beat(2)-64.07%
EPS beat(4)2
Avg EPS beat(4)162.41%
Min EPS beat(4)-73.27%
Max EPS beat(4)694.06%
EPS beat(8)5
Avg EPS beat(8)79.72%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-56.99%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)-0.93
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -88.62%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-137.72%
ROA(5y)-229.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.97
Quick Ratio 0.97
Altman-Z -24.35
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)6.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-123.08%
EPS Next Y94.81%
EPS Next 2Y6.4%
EPS Next 3Y8.93%
EPS Next 5Y7.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-119.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-96.21%
EBIT Next 3Y-19.42%
EBIT Next 5Y33.13%
FCF growth 1Y-61.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.98%
OCF growth 3YN/A
OCF growth 5YN/A

PROMIS NEUROSCIENCES INC / PMN FAQ

What is the fundamental rating for PMN stock?

ChartMill assigns a fundamental rating of 0 / 10 to PMN.


What is the valuation status for PMN stock?

ChartMill assigns a valuation rating of 0 / 10 to PROMIS NEUROSCIENCES INC (PMN). This can be considered as Overvalued.


What is the profitability of PMN stock?

PROMIS NEUROSCIENCES INC (PMN) has a profitability rating of 0 / 10.


What is the earnings growth outlook for PROMIS NEUROSCIENCES INC?

The Earnings per Share (EPS) of PROMIS NEUROSCIENCES INC (PMN) is expected to grow by 94.81% in the next year.